Skip to main content
main-content

01.12.2018 | Case report | Ausgabe 1/2018 Open Access

BMC Cancer 1/2018

A primary undifferentiated pleomorphic sarcoma of the lumbosacral region harboring a LMNA-NTRK1 gene fusion with durable clinical response to crizotinib: a case report

Zeitschrift:
BMC Cancer > Ausgabe 1/2018
Autoren:
Ning Zhou, Reinhold Schäfer, Tao Li, Meiyu Fang, Luying Liu
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1186/​s12885-018-4749-z) contains supplementary material, which is available to authorized users.
Abbreviations
CCR
Complete clinical response
CK
Cytokeratin
CT
Computed tomography
G-CSF
Granulocyte colony-stimulating factor
H&E
Hematoxylin and eosin
MAPK
Mitogen-activated protein kinase
MFH
Malignant fibrous histiocytoma
MRI
Magnetic resonance imaging
NGS
Next-generation sequencing
PET/CT
Positron emission tomography−computed tomography
PI3K
Phosphatidylinositol 3-kinase
PLC-γ
Phospholipase C-γ
PTV
Planning target volume
SMA
Smooth muscle actin
STS
Soft tissue sarcoma
TrkA
Tropomyosin receptor kinase A
UPS
Undifferentiated pleomorphic sarcoma

Background

Undifferentiated pleomorphic sarcoma (UPS), which is also referred to as malignant fibrous histiocytoma (MFH) according to the 2002 World Health Organization classification, is a rare and aggressive type of mesenchymal malignancy with no definitive cell of origin or specific recurrent genetic hallmarks. Extensive immunohistochemical characterization is required to differentiate UPS from other tumors. While UPS can occur throughout the body, these tumors are commonly found in the extremities and in the retroperitoneum [1, 2], and superficial lesions (subcutaneous) are rare. High-grade spindle cell sarcomas are one subtype of UPSs that is particularly challenging to accurately diagnose and effectively treat. The current 5-year overall survival rate for patients with UPSs is only 65–70%, highlighting the need for more effective treatment options [3].
At present, UPSs should be treated according to current guidelines for soft tissue sarcoma (STS), because no standard treatment strategy specific for UPSs has been established. Extensive excision and radiotherapy remain the cornerstones of treatment for non-metastatic tumors. With the majority of these tumors being high grade at diagnosis, localized treatments commonly result in poor local control and poor survival. Perioperative chemotherapy was recently reported to be beneficial in terms of overall survival [4], and doxorubicin as a single agent or in combination with ifosfamide is the first choice of chemotherapy in cases of UPS metastasis. A more complete understanding of the molecular characteristics and cytogenetics of these tumors will aid in the differentiation of sarcoma subtypes and development of specifically targeted therapies. Here we report a rare case of UPS in the lumbrosacral region and review the diagnostic procedures applied in this case as well as the treatment decisions and outcomes.

Case presentation

A 45-year-old male patient presented with a complaint of progressive pain and soreness in the lumbosacral region persisting for more than 3 months. The pain radiated to the left thigh and perineum but did not affect walking. Magnetic resonance imaging (MRI) and computed tomography (CT) scans with and without intravenous contrast showed a tumor mass adjacent to the left side of the fifth lumbar spinous process. The tumor was located in the lower left part of the erector spinae and extended onto the fifth lumbar vertebra, the first sacral vertebra, and the iliac wing. Positron emission tomography with CT (PET/CT) showed a hypermetabolic lesion in the erector spinae adjacent to the left side of the fifth lumbar spinous process. No sites of regional or distant metastases were found. A core biopsy of the tumor mass revealed spindle-shaped cells with infiltrating inflammatory cells. Together the morphological and immunohistochemical features indicated a low-grade inflammatory myofibroblastic tumor. The expression profile based on immunostaining was as follows: overall positive for vimentin, CD34, ALK (SP8), and p53; focally positive for smooth muscle actin (SMA); sporadically positive for S-100; partially positive for CD68; and negative for cytokeratin (CK) (AE1/AE3), desmin, and CD117. The Ki-67 nuclear labeling index was 10%.
The patient reported no other symptoms. Physical examinations revealed no neuro-pathological signs or symptoms. He denied smoking, alcohol, or illicit drug usage. He also denied recent radiation or toxin exposure. He had no history of unintentional weight loss, fever, or chills. He had no family history of malignant or other chronic diseases, with the exception of a sister who had breast cancer.
The treatment plan of the case was discussed by our multi-disciplinary team including experts from orthopedics, neurosurgery, chemotherapy, radiotherapy, pathology, and radiology. Considering that the boundary of the tumor was unclear and involved the sacrum, a complete resection would be difficult. Therefore, we administered neoadjuvant radiotherapy to the affected area at a dose of DT 5000 cGy in 25 fractions to the planning target volume (PTV). After shrinkage of the tumor volume, the patient underwent complete extensive resection at 1 month after radiotherapy. Postoperative pathology confirmed that resection of a lesion measuring 7.5 cm × 4 cm × 3.5 cm achieved negative histological margins and indicated a classification of the specimen as a mesenchymal-derived malignant tumor involving the sacrum. Histologic examination of the resected tumor revealed undifferentiated pleomorphic spindle cells surrounding an area of geographic necrosis with frequent atypical mitosis. Microscopically, the morphology conformed to that of a high-grade spindle cell sarcoma consistent with UPS. The result from MDM2 amplification using fluorescence in situ hybridization was negative, and thus, lipogenesis on histology could be excluded (Additional file 1). The expression profile of the UPS tissue is described in Table 1, and representative images of staining tumor tissue are presented in Fig. 1.
Table 1
Expression profile of UPS tumor based on immunohistochemical staining of surgically resected tumor tissue
Positive
INI-1 (+), vimentin (+), S-100 (focally+), p53 (partially+), Bcl-2 (partially+), CD99 (+), calponin (sporadically+), Ki-67 (+, 15%), transducin-like enhancer of Split 1 (TLE1+), melan-A (focally weak+).
Negative
AE1/AE3 (−), desmin (−), CD31 (−), caldesmon (−), CK (−), EMA (−), ALK (−), SMA (−), CD117\c-kit (−), CD34 (−), MyoD1 (−), myogenin (−), CK/LMW (−), CK5/6 (−), 34βE12 (−), CAM5.2 (−), HMB45 (−), SOX10 (−), MITF (−).
A postsurgical MRI scan obtained 1 month after surgery showed postoperative changes and no obvious mass in the surgical area. The patient underwent adjuvant chemotherapy with liposomal doxorubicin and ifosfamide but had to discontinue chemotherapy after 2 cycles due to intolerance of grade 3 fatigue and grade 2 nausea. At 3 months after surgery, three new lesions were discovered in the bilateral pulmonary region on a routine follow-up CT scan (Fig. 2a). Further radiographic imaging with PET/CT showed hypermetabolic metastases involving the erector spinae of the left posterior sacral, fifth lumbar spine, sacrum, left ilium, and twelfth thoracic vertebra, accompanied by multiple lung lesions and a suspected metastasis adjacent to the spleen (Fig. 3a). At this stage, the patient refused further chemotherapy.
With the standard therapeutic options exhausted, primary tumor tissue was subjected to DNA sequencing via next-generation sequencing (NGS) with an ILLUMINA Nextseq 500 (3DMedicines, Inc.). The MasterView 381 cancer-gene panel covered 4557 exons of 365 cancer-related genes and 47 introns of 25 genes frequently rearranged in 381 cancer-related genes (Additional file 2). The genomic DNA was extracted with the QIAamp DNA formalin-fixed paraffin-embedded tissue kit (Qiagen) following the manufacturer’s protocol and quantified with the Qubit™ dsDNA HS Assay kit (Invitrogen). Bioinformatics analyses involved analyzing the clipped reads, which can be extracted by the tag information of bam files, which mapped the individual reads to the reference human genome (hg19) with bwa aligner v0.7.12. Candidate reads that were discordant or aligned in the same direction were filtered. Read pairs with reads mapped to separate chromosomes or separated by a distance of over 2 kb on the same chromosome were kept for fusion detection at the probe level. Output rearrangements contained translocation, inversion, long deletion, etc. [5]. Through this profiling, a LMNA-NTRK1 gene fusion encoding exons 1–2 of lamin A/C and exons 11–17 of the NTRK1 gene was identified (Fig. 4), and the other unlisted genes were all wild-type. The sequencing results for the LMNA-NTRK1 gene fusion are presented in Additional files 3 and 4.
After extensive discussion and consultation with the patient and his family, we initiated crizotinib therapy per os at 450 mg per day on January 23, 2017. One month later, chest CT scanning showed that all lesions in the bilateral lungs had almost disappeared, and the patient had achieved a near-complete clinical response (CCR, Fig. 2b). PET/CT imaging was repeated after 4 months of treatment and continued to show the same response to crizotinib therapy. PET/CT revealed that local FDG metabolism was slightly increased at the lesions of the fifth lumbar spine, sacrum, left ilium and left paraspinal muscle. However, with crizotinib treatment, the FDG metabolism was significantly reduced in comparison with that seen in the first PET-CT examination. The bilateral pulmonary nodules had disappeared, and the twelfth vertebra, which had shown osteolytic bone destruction, now showed signs of healing, with an increased density and a lower FDG metabolism. The volume of the left front nodule of the spleen was significantly reduced after treatment (Fig. 3b). A timeline of the treatment course is presented in Fig. 5. As of July 2018, clinical assessments in this patient showed an ongoing near-CCR of 18 months. In general, the side effects of oral administration of crizotinib at 450 mg per day were tolerable for the patient. During the course of treatment, the patient experienced grade 3 myelosuppression and grade 2 weakness, but myelosuppression could be alleviated with granulocyte colony-stimulating factor (G-CSF)-based supportive treatment.

Discussion and conclusions

Approximately 5–15% of STS lesions cannot be differentiated by current molecular technologies or immunohistochemical criteria and are therefore classified as UPSs in an exclusion-based diagnosis [6]. The morphology of the primary tumor in the present case showed an ordered storiform pattern on hematoxylin and eosin (H&E) staining and progressively dedifferentiated to a highly pleomorphic tumor without definite true histiocytic differentiation. In addition, the tumor cells were mainly spindly with elongated, tapering nuclei. Considering also the findings on immunohistochemical staining after surgery, we finally confirmed a diagnosis of high-grade spindle cell UPS. The main pathology-based differential diagnosis among different potential histological entities was based on morphology as well as the expression profile of a panel of immunocytochemical markers. Before rendering the diagnosis of UPSs, the differential diagnoses that must be excluded include dedifferentiated liposarcoma, pleomorphic liposarcoma, pleomorphic leiomyosarcoma, pleomorphic rhabdomyosarcoma, high grade and epithelioid variant of myxofibrosarcoma, poorly differentiated carcinoma, and melanoma [7]. The diagnosis of primary UPS is made easier by extensive tumor sampling, evaluation of the overall morphologic pattern, careful searching for the best-differentiated area, and determination of the specific immunophenotype to evaluate a particular lineage of differentiation. In the present case, the initial diagnostic classification was difficult.
Current knowledge on UPSs suggests an aggressive clinical course, high incidence of recurrence and metastasis compared with other histologic STS subtypes [8]. Treatment with surgery only leads to poor rates of local control and even survival. To date, the clinical benefit of adjuvant chemotherapy and radiation remains unclear. More recently, genetic studies have contributed to an increased understanding of sarcomas and provided possible therapeutic advancements by identifying genetic markers of patients most likely to respond. In the present case, we identified a LMNA-NTRK1 fusion gene comprising exons 11–17 of the NKRT1 gene and exons 1–2 of LMNA gene in the patient’s tumor. The NTRK1 gene encodes tropomyosin receptor kinase A (TrkA), which is a membrane-bound receptor that, upon neurotrophin binding, undergoes autophosphorylation and activates members of the mitogen activated protein kinase (MAPK) pathway [9, 10]. The LMNA gene (localized at chromosome 1q22) encodes a key component of the nuclear lamina that is involved in nuclear assembly and chromatin organization. TrkA does not appear to be an oncogene, but gene fusions involving NTRK1 have been shown to be oncogenic, resulting in constitutive TrkA activation [11]. Activation of this receptor initiates several key downstream signal transduction cascades, including the MAPK, phosphatidylinositol 3-kinase (PI3K), and phospholipase C-γ (PLC-γ) pathways [12] as well as promotes phosphorylation of the AKT, ERK, and PLC-γ1 fusion proteins in vitro. Strong activation of the MAPK, PLC-γ1 and PI3K pathways can be inhibited by the NTRK1 inhibitor AZ-23 [13].
At present, no direct kinase inhibitors with NTRK1 fusions have been approved by the U.S. Food and Drug Administration. Doebele et al. [14] reported the case of a 41-year-old woman with an undifferentiated soft tissue sarcoma and lung metastasis harboring a LMNA-NTRK1 gene fusion who consented to treatment with the Trk inhibitor LOXO-101. Her tumors underwent rapid and substantial regression, with improvements in pulmonary dyspnea, oxygen saturation and reductions in plasma tumor markers. In another case of congenital infantile fibrosarcoma harboring a LMNA-NTRK1 gene fusion, a complete response to crizotinib therapy over 12 weeks was reported [15]. Crizotinib is a multi-active kinase inhibitor that blocks TrkA autophosphorylation and cell growth in cells expressing NTRK1 fusion proteins [11]. Notably, targeted crizotinib therapy is superior to standard chemotherapy in lung cancer patients with ALK fusions [16]. Based on the report of a minor response to crizotinib in a case of non-small cell lung cancer harboring a NTRK1 fusion as well as preclinical data [11], we started oral administration of crizotinib (450 mg QD) in the UPS patient described in this report. Over the follow-up period, the patient did not experience intolerable adverse effects from treatment and continued crizotinib monotherapy with no evidence of disease for more than 18 months as of July 2018. To our knowledge, this is the first case of UPS with a LMNA-NTRK1 gene fusion showing a durable response to crizotinib.
After screening a total of 1272 soft tissue sarcomas, Doebele et al. [14] identified five cases with a NTRK1 gene fusion, including three pediatric cases aged < 5 years and two adults. Thus, the detection rate for NTRK1 fusions in STS was less than 1% in their study. Haller et al [17] also reported four cases of sarcomas harboring NTRK1 gene fusions. The patients were two children aged 11 months and 2 years and two adults aged 51 and 80 years. The histomorphology in these cases was also described as characteristic spindle cell features, corresponing well to observations in the present case. These findings highlight the importance of further large research series with genetic testing of any sarcomatous neoplasm with similar histomorphology features for NTRK1 gene fusion and the application of such testing in the routine clinical diagnostic setting. The tumor regression and clinical response observed in the present case establishes that this LMNA-NTRK1 fusion may be a molecular driver of carcinogenesis in this patient and provides clinical validation of a molecular target in oncology. The oncogene driver may be the dominant factor in determining the response to targeted therapy, rather than the histologic subtype. We will continue following the clinical course of the patient to monitor the duration of the response, investigate how crizotinib has impacted the tumor, and track the potential development of treatment resistance.
In summary, this case provides robust evidence for the importance of molecular evaluation in cases of these rare but aggressive lesions and stresses the need for the development of drugs for better molecularly targeted STS treatment, especially when standard-of-care options have been exhausted or treatment options are unavailable.

Acknowledgments

The first author is an MD candidate in Charité Universitätsmedizin Berlin and is sponsored by Zhejiang Cancer Hospital.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding authors on reasonable request.

Ethics approval and consent to participate

Informed consent as documented by signature was obtained from this patient.

Consent for publication

Written informed consent was obtained from the patient for publication of the Case Report and any accompanying images.

Competing interests

The authors declare that they have no competing interests.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Zusatzmaterial
Additional file 1: FISH result of MDM2 amplification. (PDF 299 kb)
12885_2018_4749_MOESM1_ESM.pdf
Additional file 2: The MasterView 381 cancer-gene panel. (PDF 77 kb)
12885_2018_4749_MOESM2_ESM.pdf
Additional file 3: LMNA BLAST. (PDF 42 kb)
12885_2018_4749_MOESM3_ESM.pdf
Additional file 4: NTRK1 BLAST. (PDF 47 kb)
12885_2018_4749_MOESM4_ESM.pdf
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2018

BMC Cancer 1/2018 Zur Ausgabe


 

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise